ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2018
The prognostic value of volume-based parameters using
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 46 citations in OpenAlex.
- Glycolysis‑driven immunosuppression in gastric cancer: Metabolic crosstalk between tumor cells and the immune microenvironment (Review).International journal of oncology · 2026Review
- Development and validation of a nomogram for the non-invasive prediction of human epidermal growth factor receptor 2 expression in gastric adenocarcinoma: anJournal of gastrointestinal oncology · 2026Article
- Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance.Molecular cancer · 2026Review
- Palliative gastrectomy or gastrojejunostomy for symptomatic stage IV gastric cancer: a dual center, retrospective, propensity matched cohort study.Frontiers in oncology · 2026Article
- Article
- Radiomics-based assessment of HER2 status and prognosis in gastric cancer: a retrospective dual-center CT study.Abdominal radiology (New York) · 2025Article
- Predictive value ofBMC cancer · 2025Article
- Efficacy ofCancer reports (Hoboken, N.J.) · 2025Article
- Predictive Value of Preoperative Maximum Standardized Uptake Value (SUVmax) in Patients with Advanced Gastric Cancer.Biomedicines · 2025Article
- Predictive significance ofFrontiers in oncology · 2025Article
- Development and validation of a machine learning-basedCancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Multimodal MRI for Estimating Her-2 Gene Expression in Endometrial Cancer.Bioengineering (Basel, Switzerland) · 2023Article
- Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response.Cell reports. Medicine · 2023Article
- Predictive value ofJournal of cancer research and clinical oncology · 2023Article
- PreoperativeQuantitative imaging in medicine and surgery · 2023Article
- Molecular and functional imaging in cancer-targeted therapy: current applications and future directions.Signal transduction and targeted therapy · 2023Review
- Development and external validation of a radiomics model for assessment of HER2 positivity in men and women presenting with gastric cancer.Insights into imaging · 2023Article
- PET/CT for Predicting Occult Lymph Node Metastasis in Gastric Cancer.Current oncology (Toronto, Ont.) · 2022Review
- Evaluation of Epidermal Growth Factor Receptor 2 Status in Gastric Cancer by CT-Based Deep Learning Radiomics Nomogram.Frontiers in oncology · 2022Article
- The Relationship Between HER-2 Expression Levels andMolecular imaging and radionuclide therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundWe aimed to find the clinical value of metastatic tumor burden evaluated with F18-FDG PET/CT in gastric cancer patients, considering the human epidermal growth factor receptor 2 (HER2) status.
methodsWe retrospectively reviewed 124 patients with locally advanced or metastatic gastric cancer at Yonsei Cancer Center between January 2006 and December 2014 who had undergone baseline FDG PET/CT before first-line chemotherapy. We measured the maximum standardized uptake value from the primary tumor (SUV
resultsSUV
conclusionsHER2-positive gastric cancers had higher SUV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.